MARKET

AVDL

AVDL

Avadel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.15
-0.02
-0.22%
Closed 16:58 09/24 EDT
OPEN
9.17
PREV CLOSE
9.17
HIGH
9.49
LOW
9.01
VOLUME
660.83K
TURNOVER
--
52 WEEK HIGH
10.33
52 WEEK LOW
4.900
MARKET CAP
535.16M
P/E (TTM)
-9.5402
1D
5D
1M
3M
1Y
5Y
Needham Initiates Coverage With Buy For This Narcolepsy Player
Benzinga · 3d ago
Biogen, Sage are new buys as Needham initiates coverage on neuro-focused stocks
Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) have been granted buy ratings at Needham as the firm initiated the coverage on companies focused on neurological diseases despite hurdles for therapeutic development
Seekingalpha · 3d ago
DPW, JOBY and CEI among pre market gainers
MEDIROM Healthcare Technologies (NASDAQ:MRM) +77% on deal for ZACC Kabushiki Kaisha Digital Brands (NASDAQ:DBGI) +27%. TransCode Therapeutics (NASDAQ:RNAZ) +15% announces publication in cancer nanotechnology of preclinical data supporting therapeutic poten...
Seekingalpha · 3d ago
Needham Initiates Coverage On Avadel Pharmaceuticals with Buy Rating, Announces Price Target of $17
Needham analyst Ami Fadia initiates coverage on Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy rating and announces Price Target of $17.
Benzinga · 4d ago
Needham Starts Avadel Pharmaceuticals at Buy With $17 Price Target
MT Newswires · 4d ago
Avadel Recognizes World Narcolepsy Day And Announces New Data Presentations From Pivotal Phase 3 REST-ON Trial Of FT218 At Upcoming Conference
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced its support of the third annual World Narcolepsy Day on Wednesday, September 22. FT218 is the
Benzinga · 6d ago
11 Stocks to Buy Now According to Jeffrey Gendell’s Tontine Asset Management
In this article, we discuss the 11 stocks to buy now according to Jeffrey Gendell’s Tontine Asset Management based on Q2 holdings of the fund. If you want to skip our detailed analysis of Gendell’s history, investment philosophy, and hedge fund performance...
Insider Monkey · 09/03 13:32
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in ...
GlobeNewswire · 09/02 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVDL. Analyze the recent business situations of Avadel through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVDL stock price target is 18.25 with a high estimate of 23.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 122
Institutional Holdings: 47.50M
% Owned: 81.22%
Shares Outstanding: 58.49M
TypeInstitutionsShares
Increased
26
1.63M
New
11
374.56K
Decreased
16
1.66M
Sold Out
8
401.24K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Geoffrey Glass
Chief Executive Officer/Chief Operating Officer/Executive Vice President/Director
Gregory Divis
Chief Financial Officer
Thomas McHugh
Other
Richard Kim
Independent Director
Eric Ende
Independent Director
Mark McCamish
Independent Director
Linda Palczuk
Independent Director
Peter Thornton
No Data
  • All
  • Financials
  • Insiders
More
About AVDL
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

Webull offers kinds of Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ:AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.